FindTrial
Sign In

Association of Novel Serum-Derived Biomarkers of Inflammation, Metabolism, and Insulin Resistance in Coronary Heart Disease Patients with Hyperuricemia

Association of Novel Serum-Derived Biomarkers of Inflammation, Metabolism, and Insulin Resistance in Coronary Heart Disease Patients with Hyperuricemia

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600117108
Enrollment
Unknown
Registered
2026-01-20
Start date
2026-01-20
Completion date
Unknown
Last updated
2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CHD

Interventions

Hyperuricemia group:none
Non-Hyperuricemia group:none

Sponsors

Northern Jiangsu People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: (1) Age >=18 years; all subjects underwent complete coronary angiography, with diagnostic angiography revealing >=50% stenosis in any coronary artery or its major branch.

Exclusion criteria

Exclusion criteria: (1) History of old myocardial infarction, coronary artery bypass grafting, or percutaneous coronary intervention, along with concomitant valvular heart disease, rheumatic heart disease, dilated cardiomyopathy, hypertrophic cardiomyopathy, or other organic heart diseases; (2) Concomitant malignant arrhythmias, severe cardiopulmonary insufficiency, hepatic or renal insufficiency, rheumatic immune disorders, or neoplastic/hematologic diseases; (3) Incomplete clinical documentation.

Design outcomes

Primary

MeasureTime frame
Alternative Markers of Insulin Resistance;—

Countries

China

Contacts

Public ContactJing Zhang

Northern Jiangsu People's Hospital

zhangjingyjs@163.com+86 159 5273 9006

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026